Bayer's Crop Science Surge Masks a Broader H1 Slowdown

The first-quarter headline was easy to love. Core earnings per share of €2.71, up 12.9% year over year, powered by Crop Science margins near 40%. The consensus for Q1 ADR earnings was 64 cents; Bayer came in at 79. That looked like a turnaround quarter.

The second quarter, released today, changed the rhythm. Core EPS fell 16.7% to €0.95. Group sales grew only 2.2% on a currency- and portfolio-adjusted basis to €10.9 billion. EBITDA before special items ticked up 1.9% to €2.1 billion. The two quarters together show a first half that is impressive in one segment and quiet in the rest.

No number tells the whole story until you compare it to the business that produced it - and to what's sitting on the balance sheet.

Crop Science: the margin number you should memorize

In Q1, Crop Science posted an EBITDA margin before special items of 39.9%, up 6.2 percentage points. That is an unusually high figure for an agricultural-input company, where raw material costs, weather sensitivity, and commodity price cycles normally compress returns. The margin expansion came from two places: seed business growth and controlled input costs from efficiency programs.

Soybean Seed & Traits sales more than doubled (currency- and portfolio-adjusted), adding €448 million to the topline from the resolution of a licensing agreement with Corteva in North America and from price recovery after the dicamba label returned in the United States. Corn Seed & Traits grew 7.1%, driven by higher early-season volumes in North America and solid performance across all other regions.

Then the picture narrows. Herbicides declined 10.2% (currency- and portfolio-adjusted), with glyphosate-based products down 15.1%. Fungicides fell 10.7%. Insecticides were down 8.3%. Vegetable Seeds dropped 12.4% on demand shifts and acreage reductions. The crop protection side of the business is weakening - not a surprise, but a structural headwind that the seed growth has to outpace for the division's momentum to hold.

Q2 Crop Science margins were around 29.2%, meaningful but well below the Q1 peak. The Corteva resolution was a one-time contribution, and without it, the margin trajectory depends on whether seed volumes and pricing power hold through the rest of the planting season. If herbicides continue to slide, the division's overall margin will trend lower even if seeds stay strong.

Pharmaceuticals: flat topline, uneven mix

Pharmaceuticals sales held roughly even with the prior year in Q1, at €4.25 billion. Nubeqa (the cancer drug) and Kerendia (for chronic kidney disease) posted significant gains. Xarelto (the blood thinner) declined sharply on patent expiration. Eylea (the ophthalmology drug) fell 20.5% to €623 million on competitive and pricing pressure from generics.

That mix is the current state of a pipeline transition. The launch drugs are growing fast enough to keep the segment from deteriorating, but they haven't yet replaced the revenue that patents have taken out. A flat pharmaceutical segment is not a disaster - it's a holding pattern. The question is whether Nubeqa and Kerendia growth accelerates quickly enough to turn flat into positive before the launch curve flattens.

The litigation drag is structural, not a one-off

Here is the number most headlines skip: litigation provisions and liabilities jumped from €7.8 billion to €11.8 billion following the February announcement of the proposed $7.25 billion Roundup class settlement. The settlement caps annual payouts over 21 years, which gives Bayer a defined cost path instead of open-ended discovery risk. But it also means the cash outflow is now scheduled, not speculative.

Q1 free cash flow was minus €2.32 billion, largely from litigation settlement payments. Bayer estimates total litigation-related payouts of approximately €5 billion in 2026. Net financial debt as of March 31 stood at €32.5 billion, up 9% from year-end. The cash flow pressure is real and will show up in the balance sheet for the rest of the year.

The U.S. Supreme Court handed Bayer a partial win earlier this month, scaling back thousands of failure-to-warn claims. A Missouri state court has set an August 19 hearing for the class settlement approval. Those developments are progress, but they don't erase the €5 billion cash outflow already projected for 2026.

What the half-year tells you

Pull the two quarters together and the pattern is clear:

• Growth: Crop Science is the only division showing meaningful top-line momentum (Q1 sales +6.8%), but the seed growth was partially one-time (Corteva resolution) and partially seasonal (Q1 is the start of the North American planting cycle). Pharmaceuticals is flat. Consumer Health showed mixed results.
• Profitability: Q1 Crop Science margins of 39.9% are exceptional. Q2 at 29.2% are respectable but show the effect of losing the one-time boost. The group-level EBITDA growth of 1.9% in Q2 tells you that the other divisions didn't add much.
• Safety: Net debt of €32.5 billion, projected €5 billion in litigation payouts this year, and negative free cash flow in both reported quarters. The balance sheet is the weakest factor by far.
• Valuation context: The ADR trades near €0.34 (less than $0.40), which reflects the market's discount to the litigation overhang and the debt load. For comparison, Novartis trades at roughly 22.9x trailing earnings with €292 billion in market cap. Bayer's multiples are harder to pin down given the litigation charges flowing through the GAAP results, but the market is clearly pricing in continued legal outflows.

The first-quarter "beat" was genuine - but it was almost entirely a Crop Science story, propped up by a one-time licensing resolution and strong early-season seed demand. The second quarter's 16.7% drop in core EPS shows what the rest of the business looks like when the seed boost fades.

The portfolio question

A stock without a portfolio role is just data. Here's what the factor stack implies for Bayer right now:

• If you own Crop Science growth: the seed business is the entry point. Watch whether Q2 and Q3 margins can stay above the low-30% range as the Corteva effect drops out. If herbicides continue to decline double-digit while seeds plateau, the margin expansion story loses steam.
• If you own pharmaceutical pipeline: Nubeqa and Kerendia are the names to follow. The segment is flat - which is neither a sell signal nor a buy signal on its own. It's a watch-and-wait position.
• If balance sheet risk matters to your process: the €32.5 billion debt level and €5 billion projected litigation payout this year are the numbers that push Bayer into a lower-risk tolerance bracket. The $7.25 billion settlement caps the uncertainty, but the cash drain is multi-year.

The competitive headline about the earnings beat is not wrong - Q1 was a beat. But a single quarter, driven by one segment and one-time licensing income, doesn't change the structural picture. Crop Science is real progress. The rest of the business is still working its way through patent cliffs, litigation, and flat topline growth. The factor stack doesn't say the story is over - it says the recovery is uneven, and the balance sheet is the part of the equation that needs the most time to turn.

What would change the view upward? Sustained Crop Science margins above 35% without one-time contributions, pharmaceutical sales turning positive for two consecutive quarters, and free cash flow returning to positive territory as litigation payments decline toward the back end of the payout schedule. Those three signals together would tell you the turnaround is no longer segmented - it's group-wide.

Until then, the factor question isn't whether Crop Science is improving. It is whether that improvement is enough to offset the drag coming from the other side of the ledger.